Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Freenome, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
FRNM
Nasdaq
2836
www.freenome.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Freenome, Inc.
Tempus AI And 2 More AI Healthcare Stocks
- Nov 14th, 2026 11:08 pm
Freenome Q3 Earnings Call Highlights
- Nov 10th, 2026 7:14 pm
Freenome Reports Third Quarter 2026 Financial Results
- Nov 10th, 2026 2:01 pm
Freenome Soars 11% on Launch of Lung Cancer Blood Test That Makes Screening “Vastly Easier”
- Oct 23rd, 2026 12:23 pm
Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option
- Oct 20th, 2026 6:30 am
Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026
- Oct 15th, 2026 2:29 pm
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
- Oct 11th, 2026 11:00 am
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
- Aug 12th, 2026 7:00 am
Freenome (FRNM) Climbed, But What Is Driving Attention Now?
- Aug 10th, 2026 9:19 pm
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
- Jul 31st, 2026 2:22 pm
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Jul 27th, 2026 6:00 am
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
- Jul 20th, 2026 2:01 pm
Scroll